• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静态和动态 Ga-FAPI PET/CT 用于检测胰腺导管内乳头状黏液性肿瘤的恶性转化。

Static and Dynamic Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas.

机构信息

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

出版信息

J Nucl Med. 2023 Feb;64(2):244-251. doi: 10.2967/jnumed.122.264361. Epub 2022 Jul 29.

DOI:10.2967/jnumed.122.264361
PMID:35906094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9902850/
Abstract

Pancreatic ductal adenocarcinoma (PDAC) may arise from intraductal papillary mucinous neoplasms (IPMN) with malignant transformation, but a significant portion of IPMN remains to show benign behavior. Therefore, it is important to differentiate between benign IPMN and IPMN lesions undergoing malignant transformation. However, nonoperative differentiation by ultrasound, CT, MRI, and carbohydrate antigen 19-9 (CA19-9) is still unsatisfactory. Here, we assessed the clinical feasibility of additional assessment of malignancy by PET using Ga-labeled fibroblast activation protein inhibitors (Ga-FAPI PET) in 25 patients with MRI- or CT-proven cystic pancreatic lesions. Twenty-five patients with cystic pancreatic lesions who were followed up in the European Pancreas Center of Heidelberg University hospital and who were led to surgical resection or fine-needle aspiration due to suspicious clinical, laboratory chemistry, or radiologic findings were examined by static (all patients) and dynamic (20 patients) Ga-FAPI PET. Cystic pancreatic lesions were delineated and SUV and SUV were determined. Time-activity curves and dynamic parameters (time to peak, , , K3, ) were extracted from dynamic PET data. Receiver-operating curves of static and dynamic PET parameters were calculated. Eleven of the patients had menacing IPMN (high-grade IPMN with [6 cases] or without [5 cases] progression into PDAC) and 11 low-grade IPMN; 3 patients had other benign entities. Menacing IMPN showed significantly elevated Ga-FAPI uptake compared with low-grade IPMN and other benign cystic lesions. In dynamic imaging, menacing IPMN showed increasing time-activity curves followed by slow decrease afterward; time-activity curves of low-grade IPMN showed an immediate peak followed by rapid decrease for about 10 min and slower decrease for the rest of the time. Receiver-operating curves showed high sensitivity and specificity (area under the curve greater than 80%) of static and dynamic PET parameters for the differentiation of IPMN subtypes. Ga-FAPI PET is a helpful new tool for the differentiation of menacing and low-grade IPMN and shows the potential to avoid unnecessary surgery for nonmalignant pancreatic IPMN.

摘要

胰腺导管腺癌 (PDAC) 可能起源于具有恶性转化的导管内乳头状黏液性肿瘤 (IPMN),但很大一部分 IPMN 仍表现出良性行为。因此,区分良性 IPMN 和恶性转化的 IPMN 病变非常重要。然而,超声、CT、MRI 和糖链抗原 19-9(CA19-9)的非手术区分仍然不尽人意。在这里,我们评估了使用 Ga 标记的成纤维细胞激活蛋白抑制剂 (Ga-FAPI PET) 通过 PET 对 25 例 MRI 或 CT 证实的胰腺囊性病变患者进行恶性肿瘤额外评估的临床可行性。

我们对在海德堡大学欧洲胰腺中心接受随访的 25 例胰腺囊性病变患者进行了静态(所有患者)和动态(20 例患者)Ga-FAPI PET 检查,这些患者因可疑的临床、实验室化学或影像学发现而需要手术切除或细针抽吸。描绘胰腺囊性病变并确定 SUV 和 SUV。从动态 PET 数据中提取时间-活性曲线和动态参数(达峰时间、、、K3、)。计算静态和动态 PET 参数的受试者工作特征曲线。

11 例患者为恶性 IPMN(高级别 IPMN [6 例] 或无 [5 例] 进展为 PDAC),11 例为低级别 IPMN;3 例患者为其他良性实体。恶性 IPMN 与低级别 IPMN 和其他良性囊性病变相比,Ga-FAPI 摄取明显升高。在动态成像中,恶性 IPMN 显示出逐渐增加的时间-活性曲线,随后缓慢下降;低级别 IPMN 的时间-活性曲线显示出立即的峰值,随后在大约 10 分钟内迅速下降,其余时间缓慢下降。受试者工作特征曲线显示静态和动态 PET 参数对 IPMN 亚型的区分具有很高的敏感性和特异性(曲线下面积大于 80%)。

Ga-FAPI PET 是区分恶性和低级别 IPMN 的一种有用的新工具,显示出避免对非恶性胰腺 IPMN 进行不必要手术的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1251/9902850/ab3a850f5329/jnumed.122.264361absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1251/9902850/ab3a850f5329/jnumed.122.264361absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1251/9902850/ab3a850f5329/jnumed.122.264361absf1.jpg

相似文献

1
Static and Dynamic Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas.静态和动态 Ga-FAPI PET/CT 用于检测胰腺导管内乳头状黏液性肿瘤的恶性转化。
J Nucl Med. 2023 Feb;64(2):244-251. doi: 10.2967/jnumed.122.264361. Epub 2022 Jul 29.
2
Immunohistochemical FAP Expression Reflects Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma.免疫组化 FAP 表达反映低级别和高级别导管内乳头状黏液性肿瘤和胰腺导管腺癌的 Ga-FAPI PET 成像特性。
J Nucl Med. 2024 Jan 2;65(1):52-58. doi: 10.2967/jnumed.123.266393.
3
Comparing the clinical value of baseline [ Ga]Ga-FAPI-04 PET/CT and [F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis.对比基线 [68Ga]Ga-FAPI-04 PET/CT 和 [18F]F-FDG PET/CT 在胰腺导管腺癌中的临床价值:远端胰腺炎的附加预后价值。
Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4036-4050. doi: 10.1007/s00259-023-06297-y. Epub 2023 Jul 26.
4
Comparison of early and late Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas.33 例胰腺导管腺癌可疑复发患者的 Ga-FAPI-46-PET 早期与晚期比较。
Sci Rep. 2023 Oct 19;13(1):17848. doi: 10.1038/s41598-023-43049-2.
5
Tumor Characterization by [Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial.[Ga]FAPI-46 PET/CT 对肿瘤特征的描述可改善胰腺癌患者的治疗选择:一项前瞻性临床试验的中期分析。
J Nucl Med. 2023 Aug;64(8):1232-1237. doi: 10.2967/jnumed.123.265481. Epub 2023 Jun 22.
6
Prognostic value of preoperative [ Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics.术前 [Ga]Ga-FAPI-04 PET/CT 对可切除胰腺导管腺癌患者的预后价值与免疫组织化学特征的相关性。
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1780-1791. doi: 10.1007/s00259-022-06100-4. Epub 2023 Jan 25.
7
Impact of Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas.Ga-FAPI PET/CT 成像对原发性和复发性胰腺导管腺癌治疗管理的影响。
J Nucl Med. 2021 Jun 1;62(6):779-786. doi: 10.2967/jnumed.120.253062. Epub 2020 Oct 23.
8
Pre-operative nomogram predicting malignant potential in the patients with intraductal papillary mucinous neoplasm of the pancreas: focused on imaging features based on revised international guideline.术前列线图预测胰腺内导管乳头状黏液性肿瘤患者的恶性潜能:基于修订后的国际指南的影像学特征重点。
Eur Radiol. 2020 Jul;30(7):3711-3722. doi: 10.1007/s00330-020-06736-6. Epub 2020 Feb 24.
9
Diagnostic Potential of Supplemental Static and Dynamic Ga-FAPI-46 PET for Primary F-FDG-Negative Pulmonary Lesions.静态和动态 Ga-FAPI-46 PET 对原发性 F-FDG 阴性肺部病变的诊断潜力。
J Nucl Med. 2024 Jun 3;65(6):872-879. doi: 10.2967/jnumed.123.267103.
10
Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.2-[18F]氟代-2-脱氧-D-葡萄糖正电子发射断层扫描在胰腺内导管乳头状黏液性肿瘤良恶性鉴别诊断中的应用。
Oncol Rep. 2010 Sep;24(3):613-20. doi: 10.3892/or_00000899.

引用本文的文献

1
Image analysis: Ga-FAPI-46 PET derived texture parameters improve the differentiation of malignant and benign pulmonary lesions.图像分析:镓标记的FAPI-46正电子发射断层扫描(PET)衍生的纹理参数可提高肺恶性和良性病变的鉴别能力。
Cancer Imaging. 2025 Jun 12;25(1):73. doi: 10.1186/s40644-025-00886-w.
2
Dynamic FDG PET/CT imaging: quantitative assessment, advantages and application in the diagnosis of malignant solid tumors.动态氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描成像:定量评估、优势及在恶性实体瘤诊断中的应用
Front Oncol. 2025 Apr 14;15:1539911. doi: 10.3389/fonc.2025.1539911. eCollection 2025.
3
Clinical Utility of Fluorine-Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography in the Evaluation of Pancreatic Ductal Adenocarcinoma: Comparison With Fluorine-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

本文引用的文献

1
Pancreatic Cancer: A Review.胰腺癌:综述。
JAMA. 2021 Sep 7;326(9):851-862. doi: 10.1001/jama.2021.13027.
2
F-labeled tracers targeting fibroblast activation protein.靶向成纤维细胞活化蛋白的F标记示踪剂。
EJNMMI Radiopharm Chem. 2021 Aug 21;6(1):26. doi: 10.1186/s41181-021-00144-x.
3
Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.成纤维细胞激活蛋白特异性 PET/CT 成像在肺纤维化性间质性肺疾病和肺癌中的应用:一项转化性探索性研究。
氟-成纤维细胞激活蛋白抑制剂-04正电子发射断层扫描/计算机断层扫描在胰腺导管腺癌评估中的临床应用:与氟-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的比较
MedComm (2020). 2025 Mar 10;6(3):e70136. doi: 10.1002/mco2.70136. eCollection 2025 Mar.
4
Systematic review and meta-analysis of the prognostic role of fibroblast-activation protein in gastrointestinal cancers.成纤维细胞激活蛋白在胃肠道癌症中预后作用的系统评价和荟萃分析
J Gastrointest Oncol. 2024 Dec 31;15(6):2447-2459. doi: 10.21037/jgo-24-374. Epub 2024 Dec 24.
5
Advancements in early detection of pancreatic cancer: the role of artificial intelligence and novel imaging techniques.胰腺癌早期检测的进展:人工智能和新型成像技术的作用。
Abdom Radiol (NY). 2025 Apr;50(4):1731-1743. doi: 10.1007/s00261-024-04644-7. Epub 2024 Oct 28.
6
Prospective Comparison of [F]FDG and [F]AIF-FAPI-74 PET/CT in the Evaluation of Potentially Resectable Pancreatic Ductal Adenocarcinoma.[F]FDG与[F]AIF-FAPI-74 PET/CT在评估潜在可切除胰腺导管腺癌中的前瞻性比较
Mol Imaging Biol. 2024 Dec;26(6):1068-1077. doi: 10.1007/s11307-024-01950-w. Epub 2024 Oct 4.
7
Pancreatic Cancer: A Review of Risk Factors.胰腺癌:风险因素综述
Life (Basel). 2024 Aug 5;14(8):980. doi: 10.3390/life14080980.
8
Diagnostic Potential of Supplemental Static and Dynamic Ga-FAPI-46 PET for Primary F-FDG-Negative Pulmonary Lesions.静态和动态 Ga-FAPI-46 PET 对原发性 F-FDG 阴性肺部病变的诊断潜力。
J Nucl Med. 2024 Jun 3;65(6):872-879. doi: 10.2967/jnumed.123.267103.
9
Current considerations on intraductal papillary neoplasms of the bile duct and pancreatic duct.当前关于胆管和胰管内乳头状肿瘤的考虑因素。
World J Gastroenterol. 2024 Mar 14;30(10):1461-1465. doi: 10.3748/wjg.v30.i10.1461.
10
Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging.胰腺导管腺癌中的癌症相关成纤维细胞或异质性的隐喻:从单细胞分析到全身成像
Biomedicines. 2024 Mar 6;12(3):591. doi: 10.3390/biomedicines12030591.
J Nucl Med. 2022 Jan;63(1):127-133. doi: 10.2967/jnumed.121.261925. Epub 2021 Jul 16.
4
Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm.手术治疗导管内乳头状黏液性肿瘤中“观察与等待”概念的风险。
JAMA Surg. 2021 Sep 1;156(9):818-825. doi: 10.1001/jamasurg.2021.0950.
5
Dynamic PET/CT Imaging of Ga-FAPI-04 in Chinese Subjects.镓标记的FAPI-04在中国受试者中的动态PET/CT成像
Front Oncol. 2021 Mar 11;11:651005. doi: 10.3389/fonc.2021.651005. eCollection 2021.
6
A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic Ga-FAPI-04 PET/CT imaging.一项关于健康组织、肝细胞癌及其他病变的动态镓- FAPI - 04 PET/CT成像的方法学研究。
EJNMMI Phys. 2021 Jan 22;8(1):8. doi: 10.1186/s40658-021-00353-y.
7
The diagnostic role of CT, MRI/MRCP, PET/CT, EUS and DWI in the differentiation of benign and malignant IPMN: A meta-analysis.CT、MRI/MRCP、PET/CT、EUS 和 DWI 在鉴别良恶性胰胆管内乳头状黏液瘤中的诊断作用:一项荟萃分析。
Clin Imaging. 2021 Apr;72:183-193. doi: 10.1016/j.clinimag.2020.11.018. Epub 2020 Dec 2.
8
Impact of Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas.Ga-FAPI PET/CT 成像对原发性和复发性胰腺导管腺癌治疗管理的影响。
J Nucl Med. 2021 Jun 1;62(6):779-786. doi: 10.2967/jnumed.120.253062. Epub 2020 Oct 23.
9
The value of F-FDG positron emission tomography to differentiate benign from malignant intraductal papillary mucinous neoplasms: A prospective multicenter study.F-FDG 正电子发射断层扫描对鉴别良性和恶性导管内乳头状黏液性肿瘤的价值:一项前瞻性多中心研究。
J Visc Surg. 2020 Oct;157(5):387-394. doi: 10.1016/j.jviscsurg.2020.01.006. Epub 2020 Jan 28.
10
Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.镓-FAPI PET/CT:28 种不同癌症的示踪剂摄取。
J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.